Mometasone Sandoz (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasone Sandoz, is a corticosteroid presented as a nasal spray for nasal use. It treats inflammatory nasal conditions such as allergic rhinitis and nasal polyps in patients requiring prescription therapy.

GNH USA supplies Mometasone Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone Sandoz is a topical corticosteroid that acts on the nasal mucosa to reduce inflammation in the following conditions:

- Allergic rhinitis: relieves nasal congestion, itching, sneezing and rhinorrhea. - Nasal polyps: decreases polyp size and improves nasal airflow. - Seasonal allergic rhinitis: controls symptoms triggered by seasonal allergens.

Mometasone Sandoz may cause local and systemic adverse reactions. Most are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleed). - Throat irritation or dryness. - Altered taste or bitter taste. - Cough.

Serious or Rare Side Effects: - Nasal septal perforation. - Severe allergic reaction (anaphylaxis). - Adrenal suppression with prolonged high‑dose use. - Vision changes such as cataracts or glaucoma. - Opportunistic fungal infection of the nasal passages. - Persistent hoarseness or vocal cord changes.

Before using Mometasone Sandoz, consider the following safety measures:

- Prescription only: use exactly as directed by a healthcare professional. - Avoid use in untreated bacterial, viral, or fungal nasal infections. - Monitor for signs of adrenal insufficiency during long‑term therapy. - Caution in patients with glaucoma or cataracts. - Discontinue if hypersensitivity to mometasone or any excipients occurs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mometasone Sandoz can interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Systemic corticosteroids: additive risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase local exposure.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask nasal irritation symptoms. - Nasal decongestants: combined use can increase local pressure. - Antifungal agents: potential for altered local flora. - Immunosuppressants: heightened risk of infection. - Vaccines administered intranasally: possible reduced efficacy.